We're thrilled to share the success of our recent "Viva Biotech’s 2023 Overseas Appreciation Receptions" in Boston and San Francisco, where we are able to share and exemplify some of our most recent advancements in innovative Drug Discovery services.
In the late 2000’s, a small Australian biotech – Cytopia - discovered a molecule capable of selective inhibition of JAK1/2 and activin A receptor, type I (ACVR1). Since that time, it has passed through 4 companies, both big and small who variously advanced or failed the compound, finally landing at GSK for $1.9B dollars.
Our Discovery Project Leaders and Business Development teams will be present at a number of events at the end of 2023 and in the first half of 2024, meeting with existing and new collaborators and keeping up-to-date with the latest therapeutic and technology developments to best support our clients’ programs through the Discovery process.
At SYNthesis med chem, we are working alongside colleagues at Viva Biotech to provide access to all of the services our clients need to effectively progress PROTAC and Molecular Glue projects through Discovery and into Development.
SYNthesis med chem has joined Lean Life Science’s Oncology Development Programme (ODP2), a collaboration with four of the top ten global pharma, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and over 20 specialist contract research organisations.
